Skip to main content

Century Therapeutics, Inc. (IPSC)

NASDAQ: IPSC · Delayed Price · USD
24.76 -4.49 (-15.35%)
Sep 17, 2021 4:00 PM EDT - Market closed
Market Cap1.35B
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out12.04M
EPS (ttm)-8.14
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,672,264
Open29.01
Previous Close29.25
Day's Range24.51 - 30.32
52-Week Range18.93 - 32.90
Betan/a
Analystsn/a
Price Target36.25 (+46.4%)
Est. Earnings DateNov 11, 2021

About IPSC

Century Therapeutics is an innovative biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with significant unmet medical need. We have created a comprehensive allogeneic cell therapy platform that allows us to incorporate multiple transgenes and remove target genes intended to optimize cell product performance, sophisticated protein engineering capabilities to develop proprietary next generation chimeric antigen receptors, or CARs, our ...

IndustryEnergy Equipment & Services
IPO DateJun 18, 2021
CEOOsvaldo Flores, Ph.D.
Employees121
Stock ExchangeNASDAQ
Ticker SymbolIPSC
Full Company Profile

News

Century Therapeutics Announces Its Addition to the Russell 2000® Index

PHILADELPHIA, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno...

2 days ago - GlobeNewsWire

Century Therapeutics Reports Second Quarter 2021 Financial Results and Business Updates

Continued Company investment across our iPSC platforms, programs, and manufacturing Lead program, CNTY-101, remains on track for IND filing in mid-2022 Recent IPO with net proceeds of approximately $221...

1 month ago - GlobeNewsWire

Century Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purcha...

PHILADELPHIA, June 22, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-...

2 months ago - GlobeNewsWire

Century Therapeutics Announces Pricing of Initial Public Offering

PHILADELPHIA, June 17, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics, an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today...

3 months ago - GlobeNewsWire

Century Therapeutics IPO Registration Document (S-1)

Century Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

3 months ago - SEC